BMEA News

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025